Agios Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Agios Pharmaceuticals CEO'su Brian Goff, Aug2022 tarihinde atandı, in görev süresi 3.67 yıldır. in toplam yıllık tazminatı $ 5.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.8% maaş ve 84.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.31% ine doğrudan sahiptir ve bu hisseler $ 5.18M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 3.7 yıldır.
Anahtar bilgiler
Brian Goff
İcra Kurulu Başkanı
US$5.4m
Toplam tazminat
| CEO maaş yüzdesi | 15.77% |
| CEO görev süresi | 3.7yrs |
| CEO sahipliği | 0.3% |
| Yönetim ortalama görev süresi | 4.3yrs |
| Yönetim Kurulu ortalama görev süresi | 3.7yrs |
Son yönetim güncellemeleri
Recent updates
Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade)
Apr 21
AGIO: Sickle Cell Regulatory Uncertainty Will Continue To Restrain Enthusiasm
Analysts have raised their price target on Agios Pharmaceuticals by $3 to a new fair value estimate of $28, citing recent target increases from major firms and growing attention on upcoming regulatory and clinical catalysts. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a mix of optimism around upcoming regulatory events and ongoing caution around execution risks, valuation and timing of potential catalysts.
AGIO: Upcoming Regulatory Decisions In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have adjusted the fair value estimate for Agios Pharmaceuticals to $41.50 from $39.88, citing updated price targets and expectations tied to upcoming regulatory clarity on mitapivat, as well as broader support from recent research commentary. Analyst Commentary Recent Street research on Agios Pharmaceuticals centers on price target revisions, expectations around regulatory clarity for mitapivat in sickle cell disease, and the implications of the recent approval of Aqvesme.AGIO: Regulatory Clarity On Mitapivat In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have lifted the fair value estimate for Agios Pharmaceuticals by $1 to $39.88, citing higher price targets, expectations for regulatory clarity around mitapivat in sickle cell disease, and the recent approval of Aqvesme as key drivers of their updated outlook. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Agios Pharmaceuticals, with several price target revisions clustering in the US$25 to US$46 range and commentary centered on regulatory milestones, the impact of Aqvesme, and broader biotech sector conditions.AGIO: Thalassemia Decision And Recent Approval Will Drive Next Phase Upside
Analysts have nudged their intrinsic value estimate for Agios Pharmaceuticals higher to about $38.88 from $36.75, reflecting refreshed price targets in the $25 to $35 range and updated models following recent product approval and broader biotech sector tailwinds cited in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the mid US$20s to mid US$30s, which aligns with the higher intrinsic value estimate around US$38.88 and indicates they see room for the shares to better reflect updated assumptions.AGIO: Sickle Cell Setback Will Continue To Restrain Enthusiasm Despite Thalassemia Approval
Analysts have lifted their fair value estimate for Agios Pharmaceuticals shares from $20 to $25, citing updated models that reflect recent drug approvals, ongoing FDA review milestones, and a series of higher Street price targets across the biotech sector. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a split view, with several bullish initiations and target hikes alongside more cautious revisions that highlight execution and growth risks around the company’s pipeline and commercial plans.AGIO: Thalassemia Decision And Aqvesme Approval Will Define Post RISE UP Upside
Narrative Update: Agios Pharmaceuticals (AGIO) Analysts have lifted Agios Pharmaceuticals' price targets into a US$25 to US$38 range, with recent tweaks to models reflecting the approval of Aqvesme, updated views on mitapivat and Pyrukynd, and a generally more constructive stance on U.S. biotech capital and deal activity. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a wide spread of views, with price targets clustered in the US$25 to US$38 range after earlier cuts from much higher levels.AGIO: Upcoming Thalassemia Decision Will Shape Post RISE UP Opportunity Narrative
Agios Pharmaceuticals’ fair value estimate edges up from US$36.00 to US$36.75 as analysts recalibrate models following recent target changes across the Street, reflecting updated views on Pyrukynd’s opportunity set, revised profit margin assumptions, and a higher future P/E multiple, despite some ongoing trial related uncertainties. Analyst Commentary Street research around Agios has become more divided, with some analysts leaning into the updated opportunity around Pyrukynd and other mitapivat indications, while others focus on execution risk and regulatory uncertainty following the RISE UP sickle cell disease data.AGIO: Upcoming FDA Thalassemia Decision Will Shape Post RISE UP Bullish Outlook
Analysts have lifted their aggregate fair value estimate for Agios Pharmaceuticals to $36.00 from $32.13, citing updated revenue and margin assumptions. This follows mixed views on the recent RISE UP data and new Street targets that range widely from US$20 to US$48, alongside Citi's fresh US$38 initiation and a near-term FDA catalyst watch.AGIO: Sickle Cell Setback Will Drive Cautious View Despite Upcoming FDA Decision
Analysts have cut their average price target on Agios Pharmaceuticals to $20 from $37, reflecting reduced expectations for mitapivat in sickle cell disease and more conservative long term revenue and expense assumptions, even as some still see upside around upcoming regulatory catalysts for Pyrukynd. Analyst Commentary Bearish analysts have responded to the RISE UP data by sharply recalibrating expectations for mitapivat in sickle cell disease, cutting price targets and, in some cases, ratings.AGIO: Upcoming FDA Decision Will Drive Bullish Outlook After Mixed Trial Data
Analysts have reduced their average price target on Agios Pharmaceuticals from about $42 to roughly $32 per share. This reflects higher perceived risk after mixed Phase 3 RISE UP data, tempered revenue and margin expectations, and a wider debate over the regulatory and commercial outlook for mitapivat and Pyrukynd across indications.AGIO: Regulatory Decisions Will Drive Outlook After Mixed Late-Stage Clinical Results
Agios Pharmaceuticals’ analyst price target has been reduced from approximately $47.50 to $42.33 per share. Analysts cite increased uncertainty for mitapivat in sickle cell disease following underwhelming Phase 3 trial results, as well as a more challenging regulatory and commercial pathway.FDA Approval And Global Partnerships Will Yield Mixed Prospects
Analysts modestly trimmed Agios Pharmaceuticals’ price target from $47.67 to $47.50, reflecting a brief FDA approval delay for Pyrukynd and cautious near-term modeling, while maintaining long-term conviction on the strength of clinical data and emerging commercial partnerships. Analyst Commentary Bullish analysts remain confident in FDA approval of Pyrukynd despite a three-month PDUFA delay due to the submission of a REMS for hepatocellular injury, which is viewed as a standard regulatory step and not due to new data requests.Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem
Feb 20
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Feb 14
Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges
Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Jan 14Agios Pharmaceuticals: A Long Overdue Follow Up
Dec 03We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$423m |
| Dec 31 2025 | US$5m | US$847k | -US$413m |
| Sep 30 2025 | n/a | n/a | -US$401m |
| Jun 30 2025 | n/a | n/a | US$650m |
| Mar 31 2025 | n/a | n/a | US$666m |
| Dec 31 2024 | US$7m | US$822k | US$674m |
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Tazminat ve Piyasa: Brian 'ın toplam tazminatı ($USD 5.37M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.48M ).
Tazminat ve Kazançlar: Brian 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Brian Goff (56 yo)
3.7yrs
Görev süresi
US$5,370,389
Tazminat
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. since June 2024. He has been Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. since August 08, 2022. He...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$5.37m | 0.31% $ 5.2m | |
| Chief Financial Officer | 3.6yrs | US$2.52m | 0.094% $ 1.5m | |
| Chief Legal Officer | 4.3yrs | US$2.37m | 0.084% $ 1.4m | |
| Chief Corporate Development & Strategy Officer | 1.1yrs | US$2.81m | 0.018% $ 288.4k | |
| Chief Medical Officer and Head of Research & Development | 4.6yrs | US$2.09m | 0.14% $ 2.3m | |
| Co-Founder | no data | US$333.51k | Veri yok | |
| Co-Founder | no data | Veri yok | Veri yok | |
| Co-Founder | no data | Veri yok | Veri yok | |
| Co-Founder | no data | Veri yok | Veri yok | |
| VP, Controller & Principal Accounting Officer | 4.7yrs | Veri yok | 0.0015% $ 24.3k | |
| Chief Technical Operations Officer | 8.8yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok |
4.3yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: AGIO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$5.37m | 0.31% $ 5.2m | |
| Chair of the Board of Directors | 8.3yrs | US$492.16k | 0.26% $ 4.2m | |
| Independent Director | 2.8yrs | US$469.66k | 0.010% $ 170.3k | |
| Lead Independent Director | 11.3yrs | US$498.41k | 0.013% $ 209.5k | |
| Independent Director | less than a year | US$657.15k | Veri yok | |
| Independent Director | 10.8yrs | US$464.66k | 0.029% $ 477.8k | |
| Independent Director | 3.7yrs | US$467.16k | 0.021% $ 348.3k | |
| Independent Director | 3.7yrs | US$467.16k | 0.021% $ 348.3k | |
| Independent Director | 8.9yrs | US$469.66k | 0.030% $ 493.7k | |
| Independent Director | 2.8yrs | US$458.41k | 0.010% $ 170.3k |
3.7yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AGIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/04/30 06:32 |
| Gün Sonu Hisse Fiyatı | 2026/04/30 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Agios Pharmaceuticals, Inc. 29 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |